Skip to main content

Healthy Volunteers

680
Pipeline Programs
30
Companies
50
Clinical Trials
3 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
648
10
9
0
2
11
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
5459%
Monoclonal Antibody
1921%
Peptide
1213%
Vaccine
55%
RNA Therapeutic
22%
+ 1090 programs with unclassified modality

On Market (1)

Approved therapies currently available

Bayer
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAINApproved
aspirin
Bayer
oral2001

Competitive Landscape

310 companies ranked by most advanced pipeline stage

Pfizer
67 programs
63
4
CelecoxibPhase 4Small Molecule1 trial
NelfinavirPhase 4Small Molecule1 trial
Nelfinavir and OmeprazolePhase 4Small Molecule
artesunate sachetsPhase 41 trial
1 x 30 mg/mL pegvisomantPhase 11 trial
+62 more programs
Active Trials
NCT01893866Completed17Est. Oct 2013
NCT03929510Completed6Est. Jul 2019
NCT01314898Completed12Est. Jun 2011
+61 more trials
Sandoz
11 programs
8
1
1
LumiracoxibPhase 4Small Molecule1 trial
DarifenacinPhase 21 trial
BPR277 ointmentPhase 11 trial
EDI048Phase 11 trial
INE 963Phase 11 trial
+6 more programs
Active Trials
NCT05429775Completed12Est. Jan 2019
NCT01428297Completed12Est. Feb 2014
NCT05275855Completed110Est. Dec 2024
+8 more trials
Bayer
6 programs
6
1
BAY1817080Phase 11 trial
BAY1830839Phase 11 trial
BAY1834845Phase 11 trial
NiclosamidePhase 11 trial
RosuvastatinPhase 1Small Molecule1 trial
+1 more programs
Active Trials
NCT04802343Completed39Est. Oct 2021
NCT03965728Completed67Est. May 2022
NCT03493269Completed72Est. Feb 2021
+2 more trials
Galderma
4 programs
1
2
Lidocaine 7% + Tetracaine 7% creamPhase 41 trial
Restylane LidocainePhase 41 trial
NemolizumabPhase 1Monoclonal Antibody1 trial
RestylaneN/A1 trial
Active Trials
NCT02565784Completed100Est. Sep 2018
NCT05405985Completed192Est. Dec 2022
NCT01545765Completed30Est. May 2012
+1 more trials
Oregon Therapeutics
1
AcarbosePhase 41 trial
MF-HIITN/A
Strength and Balance in Gender- and Age-Matched ControlsN/A1 trial
Active Trials
NCT02110875Completed25Est. Feb 2014
NCT02589353Completed157Est. Feb 2023
Kite Pharma
3 programs
2
1
Genvoya Oral dosePhase 41 trial
CB-0406 100 mgPhase 11 trial
GS-4774Phase 11 trial
Active Trials
NCT04467684Completed90Est. Jun 2021
NCT01779505Completed60Est. Aug 2013
NCT03717129Completed12Est. Nov 2021
Sensimed
1 program
1
SENSIMED TriggerfishPhase 41 trial
Active Trials
NCT01972997Completed14Est. Mar 2014
Biocodex
3 programs
1
1
etifoxinePhase 31 trial
StiripentolPhase 11 trial
Saccharomyces boulardiiN/A1 trial
Active Trials
NCT01473368Completed53Est. Feb 2013
NCT03866928Completed14Est. Apr 2019
NCT02147548Completed31Est. Oct 2015
Emergent BioSolutions
1
1
hepatitis B vaccinePhase 3Vaccine1 trial
Botulism Antitoxin BivalentPhase 1
Active Trials
NCT01311674Terminated141Est. Mar 2011
AstraZeneca
57 programs
53
4
PRT064445/ApixabanPhase 21 trial
PRT064445/EdoxabanPhase 21 trial
PRT064445/EnoxaparinPhase 21 trial
PRT064445/RivaroxabanPhase 21 trial
AZD0328Phase 11 trial
+52 more programs
Active Trials
NCT00738959Completed64Est. Oct 2008
NCT06103877Completed108Est. Jan 2026
NCT00945178Terminated11Est. Sep 2009
+52 more trials
Otsuka
10 programs
9
1
Tolvaptan 15 MGPhase 21 trial
ACH-000029Phase 11 trial
Centanafadine SRPhase 11 trial
OPC-167832Phase 11 trial
Rebamipide SR 150mgPhase 11 trial
+5 more programs
Active Trials
NCT05363839Terminated8Est. Nov 2022
NCT07465731Completed62Est. Mar 2023
NCT07542847Completed24Est. Dec 2022
+7 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
3 programs
1
1
IV MethylnaltrexonePhase 21 trial
MethylnaltrexonePhase 11 trial
Poly-L-Lactic Acid InjectionN/A1 trial
Active Trials
NCT00869687Completed14Est. May 2010
NCT01363323Completed546Est. Feb 2005
NCT01367587Completed12Est. Jul 2002
Angeles Therapeutics
1
POMxPhase 21 trial
AvocadoN/A1 trial
Active Trials
NCT01397071Completed11Est. Aug 2012
NCT01950221Completed212Est. Oct 2015
Nordic Pharma
1 program
1
Fish OilPhase 21 trial
Active Trials
NCT02628483Completed60Est. Dec 2016
Genentech
17 programs
15
1
RO5024048Phase 1/21 trial
BalovaptanPhase 11 trial
BalovaptanPhase 11 trial
Entrectinib Form APhase 11 trial
Entrectinib Test FormulationPhase 11 trial
+12 more programs
Active Trials
NCT03381144Terminated66Est. Apr 2019
NCT03586726Completed16Est. Nov 2018
NCT03579719Completed15Est. Nov 2018
+14 more trials
Syneos Health
10 programs
9
1
RPh201, botanical drug productPhase 1/21 trial
ACH-000029Phase 1
APL-1202Phase 11 trial
ASAPhase 11 trial
Forsteo®Phase 11 trial
+5 more programs
Active Trials
NCT06435039Terminated12Est. Jul 2024
NCT05625334Completed86Est. Mar 2023
NCT07497503Recruiting48Est. Jun 2026
+6 more trials
Purdue Pharma
6 programs
4
1
MF-HIITPhase 1/21 trial
Buprenorphine transdermal patchPhase 11 trial
Reformulated OXYPhase 11 trial
Reformulated OXYPhase 11 trial
Reformulated OXYPhase 11 trial
+1 more programs
Active Trials
NCT06270589Recruiting60Est. May 2026
NCT01148537Completed132Est. Dec 2004
NCT01100086Completed84Est. Jun 2007
+3 more trials
Medtronic
3 programs
1
The preparation regimenPhase 1/21 trial
Bedside Respiratory Patient Monitoring System - Sensor Off StudyN/A1 trial
Nellcor USB Pulse Oximeter Monitor Interface CableN/A1 trial
Active Trials
NCT02075346Completed18Est. Nov 2013
NCT02265783Completed20Est. Nov 2014
NCT01575093Completed25Est. Jun 2012
Rhizen Pharmaceuticals
1
1
RP3128Phase 1/21 trial
RP7214Phase 11 trial
Active Trials
NCT04680429Completed42Est. Jul 2021
NCT02958982Terminated57Est. Feb 2018
Prothya Biosolutions
1
CofactPhase 1/21 trial
Active Trials
NCT05205863Completed69Est. Sep 2022
Ingenia Therapeutics
1
IGT-303Phase 1/21 trial
Active Trials
NCT07231679Recruiting94Est. Jan 2027
Juvena Therapeutics
1
JUV-161Phase 1/21 trial
Active Trials
NCT07397468Recruiting36Est. Aug 2026
Nihon Pharmaceutical
1
NPF-08Phase 1/21 trial
Active Trials
NCT03423771Completed90Est. Feb 2018
Theriva Biologics
1
Period 1 - Treatment Sequence ABPhase 1/21 trial
Active Trials
NCT02419001Completed11Est. Oct 2015
Prevail Therapeutics
81
AtorvastatinPhase 1Small Molecule1 trial
AxironPhase 11 trial
BaricitinibPhase 1Small Molecule1 trial
BaricitinibPhase 1Small Molecule1 trial
BaricitinibPhase 1Small Molecule1 trial
+76 more programs
Active Trials
NCT01250834Completed27Est. Mar 2011
NCT02004132Completed12Est. Dec 2013
NCT01960140Completed40Est. Dec 2013
+78 more trials
AbbVie
26 programs
22
ABBV-141Phase 11 trial
ABBV-243Phase 1
ABBV-277Phase 1
ABBV-552Phase 11 trial
ABBV-668 IRPhase 11 trial
+21 more programs
Active Trials
NCT01252147Completed68Est. Dec 2010
NCT02417077Completed393Est. Dec 2015
NCT01969162Completed35Est. Nov 2013
+19 more trials
Astellas
22 programs
22
14C-labeled ASP0367Phase 11 trial
ASP015KPhase 11 trial
ASP1128Phase 11 trial
ASP1517Phase 11 trial
ASP1517Phase 12 trials
+17 more programs
Active Trials
NCT05217901Completed9Est. May 2022
NCT02141425Completed16Est. Apr 2014
NCT04742517Completed102Est. Sep 2018
+20 more trials
Human BioSciences
2
Botulism Antitoxin BivalentPhase 11 trial
REGN3470-3471-3479Phase 11 trial
BlackberriesN/A1 trial
Brain computer Interface MuN/A1 trial
Broccoli consumptionN/A1 trial
+11 more programs
Active Trials
NCT01293617Completed52Est. Apr 2011
NCT02169375Terminated6Est. Jun 2011
NCT03287115Completed6Est. Nov 2017
+9 more trials
Biocorp
13 programs
12
ASP1517Phase 11 trial
BPN-14967Phase 11 trial
BudoprutugPhase 11 trial
CLYM116Phase 11 trial
FZJ-003Phase 11 trial
+8 more programs
Active Trials
NCT03268447Completed120Est. Jan 2018
NCT02693613Completed34Est. Apr 2016
NCT04005807Completed40Est. Dec 2019
+10 more trials
Spero Therapeutics
13
SPR206Phase 11 trial
SPR206Phase 11 trial
SPR720Phase 11 trial
SPR720 for SADPhase 11 trial
SPR741Phase 11 trial
+8 more programs
Active Trials
NCT03792308Completed94Est. Dec 2019
NCT04868292Completed34Est. Sep 2021
NCT05966688Completed39Est. Feb 2024
+10 more trials

+280 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
ModernamRNA-1273.712
Novo NordiskSemaglutide
Kite PharmaGenvoya Oral dose
Oregon TherapeuticsAcarbose
GaldermaRestylane Lidocaine
LabcorpBenzalkonium Chloride Solution
SensimedSENSIMED Triggerfish
GaldermaLidocaine 7% + Tetracaine 7% cream
PfizerCelecoxib
Pfizerartesunate sachets
SandozLumiracoxib
PfizerNelfinavir
Jasper TherapeuticsNelfinavir and Omeprazole
AstraZenecaClopidogrel
TakedaSoticlestat

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 6,513 patients across 50 trials

NCT06634797ModernamRNA-1273.712

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

Start: Oct 2024Est. completion: Jan 20251,000 patients
Phase 4Completed

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

Start: Dec 2019Est. completion: Feb 2020104 patients
Phase 4Completed
NCT03717129Kite PharmaGenvoya Oral dose

Analysis of Crushed and Whole Tablet Genvoya

Start: Apr 2019Est. completion: Nov 202112 patients
Phase 4Completed

Human Oral Detection of Glucose Olygomers

Start: Apr 2017Est. completion: Feb 2023157 patients
Phase 4Completed
NCT03127384GaldermaRestylane Lidocaine

Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne Scars

Start: Apr 2017Est. completion: Nov 201849 patients
Phase 4Completed
NCT02594449LabcorpBenzalkonium Chloride Solution

A Pharmacodynamic and Safety Study of BCS in Healthy Volunteers

Start: Oct 2015Est. completion: Mar 201620 patients
Phase 4Unknown
NCT01972997SensimedSENSIMED Triggerfish

SENSIMED Triggerfish Sensor Sizes

Start: Jul 2013Est. completion: Mar 201414 patients
Phase 4Completed
NCT01545765GaldermaLidocaine 7% + Tetracaine 7% cream

Anesthetic Effect Duration Assessment

Start: May 2012Est. completion: May 201230 patients
Phase 4Completed

Study Of Celecoxib In Healthy Subjects

Start: Nov 2009Est. completion: Apr 2010190 patients
Phase 4Completed
NCT00875030Pfizerartesunate sachets

A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets (Pfizer) Versus Single-Dose Administration Of Arsuamoon® Tablets (Guilin-China) In Healthy Subjects

Start: Jun 2009Est. completion: Jun 200940 patients
Phase 4Completed

Video Capsule Endoscopy to Investigate the Safety and Tolerability of Lumiracoxib in the Small Bowel

Start: May 2006150 patients
Phase 4Completed

Thorough QT Study of Nelfinavir

Start: Mar 2006Est. completion: Jun 200668 patients
Phase 4Completed
NCT00251030Jasper TherapeuticsNelfinavir and Omeprazole

A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects

Start: Nov 2005Est. completion: Jan 200620 patients
Phase 4Completed

Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease

Start: Jan 2004Est. completion: Mar 2006255 patients
Phase 4Completed

A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Start: Apr 2024Est. completion: Aug 20241 patients
Phase 3Terminated

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Start: Jun 2022Est. completion: Nov 202320 patients
Phase 3Completed

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis

Start: Mar 2022Est. completion: Aug 202548 patients
Phase 3Completed

A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Start: Nov 2021Est. completion: Jan 2024270 patients
Phase 3Completed

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Start: Oct 2021Est. completion: Apr 2024144 patients
Phase 3Completed

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Start: Feb 2021Est. completion: Aug 2024430 patients
Phase 3Completed

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Start: Dec 2019Est. completion: Aug 202112 patients
Phase 3Completed

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Start: Sep 2019Est. completion: Jul 2025202 patients
Phase 3Completed

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Start: Mar 2019Est. completion: Nov 202338 patients
Phase 3Terminated

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Start: May 2016Est. completion: Oct 2019212 patients
Phase 3Completed

Phase III Study of Intramuscular TAK-816 in Healthy Infants

Start: Mar 2014Est. completion: Mar 201531 patients
Phase 3Completed

Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly

Start: Dec 2013Est. completion: Oct 201531 patients
Phase 3Completed

A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain

Start: Aug 2011Est. completion: Jan 201346 patients
Phase 3Completed

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

Start: Sep 2009Est. completion: Mar 2011141 patients
Phase 3Terminated

Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers

Start: Jun 2020Est. completion: Dec 202096 patients
Phase 2/3Completed

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Start: May 2026Est. completion: Mar 202930 patients
Phase 2Recruiting

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Start: Mar 2026Est. completion: Apr 2029160 patients
Phase 2Recruiting

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Start: Mar 2026Est. completion: Jun 2027250 patients
Phase 2Enrolling By Invitation

A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

Start: May 2025Est. completion: Apr 202676 patients
Phase 2Completed

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Start: Nov 2023Est. completion: Jul 2026208 patients
Phase 2Recruiting

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Start: Oct 2023Est. completion: Nov 2026367 patients
Phase 2Active Not Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Start: Jan 2023Est. completion: Feb 202518 patients
Phase 2Terminated

Ritlecitinib for Cicatricial Alopecia

Start: Dec 2022Est. completion: Mar 202550 patients
Phase 2Completed

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Start: Nov 2022Est. completion: Mar 202987 patients
Phase 2Active Not Recruiting

Fedratinib in Combination With Nivolumab

Start: Jun 2022Est. completion: Jan 202630 patients
Phase 2Completed

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

Start: Aug 2021Est. completion: Feb 2023167 patients
Phase 2Terminated

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

Start: May 2021Est. completion: Nov 2022221 patients
Phase 2Completed

Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

Start: Aug 2020Est. completion: Feb 202441 patients
Phase 2Terminated

A Research Study Investigating Mim8 in People With Haemophilia A

Start: Jan 2020Est. completion: Oct 2023275 patients
Phase 2Completed
NCT03931369OtsukaTolvaptan 15 MG

Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)

Start: Sep 2019Est. completion: Dec 202060 patients
Phase 2Unknown

Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS)

Start: Jul 2019Est. completion: Oct 202024 patients
Phase 2Completed

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Start: Feb 2019Est. completion: Nov 20200
Phase 2Withdrawn

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Start: Oct 2018Est. completion: Jul 2021242 patients
Phase 2Completed

A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)

Start: Sep 2018Est. completion: Jul 202020 patients
Phase 2Completed

A Study of Soticlestat in Adults and Children With Rare Epilepsies

Start: Jul 2018Est. completion: Jul 2025156 patients
Phase 2Terminated

Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

Start: Apr 2017Est. completion: Dec 2020200 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 6,513 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.